Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Exagen (XGN) Invested Capital (2018 - 2025)

Historic Invested Capital for Exagen (XGN) over the last 8 years, with Q3 2025 value amounting to $41.1 million.

  • Exagen's Invested Capital rose 2402.71% to $41.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $41.1 million, marking a year-over-year increase of 2402.71%. This contributed to the annual value of $28.6 million for FY2024, which is 3081.12% down from last year.
  • Latest data reveals that Exagen reported Invested Capital of $41.1 million as of Q3 2025, which was up 2402.71% from $44.0 million recorded in Q2 2025.
  • In the past 5 years, Exagen's Invested Capital registered a high of $128.3 million during Q1 2021, and its lowest value of $27.3 million during Q1 2025.
  • For the 5-year period, Exagen's Invested Capital averaged around $67.8 million, with its median value being $51.3 million (2023).
  • Per our database at Business Quant, Exagen's Invested Capital skyrocketed by 6756.63% in 2021 and then plummeted by 4422.64% in 2023.
  • Over the past 5 years, Exagen's Invested Capital (Quarter) stood at $112.4 million in 2021, then crashed by 37.05% to $70.8 million in 2022, then crashed by 41.5% to $41.4 million in 2023, then plummeted by 30.81% to $28.6 million in 2024, then surged by 43.43% to $41.1 million in 2025.
  • Its Invested Capital was $41.1 million in Q3 2025, compared to $44.0 million in Q2 2025 and $27.3 million in Q1 2025.